
Opinion|Videos|July 24, 2024
Financial Considerations Influencing Treatment Strategies in PNH Treatment Pathway
The panelists provide their final thoughts, highlighting financial considerations in PNH treatment.
Advertisement
Episodes in this series

Video content above is prompted by the following question:
- How do financial considerations influence your treatment decision-making process?
Advertisement
Related to this article

In 459 patients with FLT3-ITD AML given high-dose anthracycline induction, a high allelic ratio was not linked to survival.

In this part 2, Kirsten Axelsen, MS, discusses racial disparities, AI in prior authorization, and payers’ readiness for the next wave of CLL therapies.

Kirsten Axelsen, MS, discusses gaps in biomarker testing, nonmedical barriers, and utilization management from a new report on access to CLL care.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Dexmedetomidine Sublingual Film as At-Home Agitation Therapy
2
FDA Grants Accelerated Approval to Neladalkib for Previously Treated ALK-Positive NSCLC
3
Emerging Threats to Cell and Gene Therapy Access
4
GLP-1s Alone Won't Solve Obesity, JAMA Summit Report Says
5

